Novartis AG vs Philip Morris International Inc.
μκ°μ λ°λ₯Έ μκ°μ΄μ‘ λΉκ΅
Novartis AG
$267.3B
μμ #55
Philip Morris International Inc.
$292.4B
μμ #51
μκ°μ λ°λ₯Έ μκ°μ΄μ‘
μ£Όμ μκ°
- Philip Morris International Inc.μ΄(κ°) 2011λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
- Novartis AGμ΄(κ°) 2013λ κΉμ§ Philip Morris International Inc.μ(λ₯Ό) μΆμνμ΅λλ€
- Philip Morris International Inc.μ΄(κ°) 2017λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
- Novartis AGμ΄(κ°) 2018λ κΉμ§ Philip Morris International Inc.μ(λ₯Ό) μΆμνμ΅λλ€
- Philip Morris International Inc.μ΄(κ°) 2025λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
μ°λλ³ λΉκ΅
| μ°λ | Novartis AG | Philip Morris International Inc. | μ λ |
|---|---|---|---|
| 2026 | $267.3B | $292.4B | Philip Morris International Inc. |
| 2025 | $227.3B | $245.5B | Philip Morris International Inc. |
| 2024 | $177.6B | $177.6B | Novartis AG |
| 2023 | $163.8B | $131.8B | Novartis AG |
| 2022 | $146.3B | $134.5B | Novartis AG |
| 2021 | $134.5B | $119.6B | Novartis AG |
| 2020 | $134.7B | $99.0B | Novartis AG |
| 2019 | $142.4B | $95.5B | Novartis AG |
| 2018 | $110.8B | $70.6B | Novartis AG |
| 2017 | $104.0B | $106.5B | Philip Morris International Inc. |
| 2016 | $89.6B | $88.7B | Novartis AG |
| 2015 | $100.4B | $81.7B | Novartis AG |
| 2014 | $103.4B | $72.0B | Novartis AG |
| 2013 | $76.6B | $73.6B | Novartis AG |
| 2012 | $59.2B | $68.5B | Philip Morris International Inc. |
| 2011 | $52.5B | $62.0B | Philip Morris International Inc. |
| 2010 | $51.1B | $44.3B | Novartis AG |
| 2009 | $50.7B | $34.8B | Novartis AG |
| 2008 | $44.5B | $29.8B | Novartis AG |